Feature | November 01, 2013

Tryton Bifurcation Stent Safe but Fails to Meet Non-Inferiority Endpoint Compared to Provisional Stenting

tryton stent, bifurcation stenting

November 1, 2013 — A clinical trial designed to measure the effectiveness of using a dedicated side branch-covering bare metal stent in true bifurcation coronary lesions found that that the strategy was safe, but the results did not establish non-inferiority compared to the currently accepted strategy of using a single stent with provisional use of a second side branch stent when indicated. The findings of the TRYTON trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
The TRYTON trial compared a new specially designed bare metal bifurcation stent to standard practice of provisional stenting. The Tryton stent is placed in the proximal main vessel extending into the side branch. A standard drug-eluting stent (DES) is then placed in the main vessel through the proximal portion of the bifurcation stent into the distal main vessel. 
 
The multicenter international study randomized 704 patients with true coronary bifurcation lesions to receive the new bifurcation stent (355 patients) or provisional stenting (349 patients). The primary endpoint was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction or target vessel revascularization at nine months. 
 
At nine months, TVF was 12.8 percent in the provisional stenting group and 17.4 percent in the Tryton stent group. 
 
However, the strategy met the secondary superiority endpoint, improving the percent diameter stenosis of the side branch at nine months. In the provisional group, the percent diameter stenosis was 38.6 and in the bifurcation stent group, the percent diameter stenosis was 31.6. In a post-hoc analysis, the Tryton stent demonstrated improved angiographic outcomes with the bifurcation stent in larger side branches (> 2.25mm side branches = 39 percent of enrolled patients). The study demonstrated a disparity between binary restenosis and clinically driven TVR for both arms, indicating that side branch angiographic restenosis is uncommonly expressed clinically. 
 
“The two-stent strategy in true bifurcations compared with the provisional strategy did not meet the non-inferiority clinical endpoint (TVF), largely due to a relatively higher frequency of peri-procedural CK-MB elevations,” said Martin Leon, M.D., professor of medicine, Columbia University College of Physicians and Surgeons, director, Center for Interventional Vascular Therapy (CIVT) at NewYork-Presbyterian Hospital / Columbia University Medical Center, founder and chairman emeritus, Cardiovascular Research Foundation (CRF) and lead investigator. “However, both strategies were safe, resulting in rare clinically significant MIs and stent thrombosis. Both also had low nine-month clinically-driven TVR with 3.6 percent occurring in the provisional group and 4.7 percent in the bifurcation stent group."
 
Leon said bifucation stents are usually more difficult to implant, but found the Tryon was easier to use. However, he said many of the lesions that would have been ideal to include in this trial were not included because operators were concerned about subjecting these patients to randomization.
 
"On the efficacy side, what we learned was that unless you put the Tryton stent into larger side branches — 2.25 or larger — then you really aren't any better than a single stent provisional strategy," Leon concluded.  
 
For more information: www.crf.org

Related Content

News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Subscribe Now